Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q2 2013 · 10-Q
Revenue$98.90K$98.90K−16.7% vs Q2 2012 Net Income-$639.00K-$639.00KN/M vs Q2 2012 EPS Diluted$0.00$0.00— vs Q2 2012 Gross Profit$55,278−31.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Operating Cash Flowderived-$16,749N/M Margins · derivedGross margin55.9%−12.4 pt vs Q2 2012
Operating margin-638.7%−477.3 pt vs Q2 2012
Net margin-646.1%−475.4 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 15, 2013 · 46 d after period end